A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).

NCT Number	NCT07649265
Lead Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions	Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease
Enrollment	63 participants
Start Date	2026-09-15
Primary Completion	2028-11-20 (estimated)
Study Completion	2028-11-20 (estimated)
Updated on ClinicalTrials.gov	2026-06-16